Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

(2011) Jan Krönke et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of minimal residual disease in acute myeloid leukemia

(2010) David Grimwade et al.   CURRENT OPINION IN ONCOLOGY

Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia

(2010) Andrea Corbacioglu et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

(2009) H. B. Ommen et al.   BLOOD

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY

Harmonization of molecular monitoring of CML therapy in Europe

(2009) M C Müller et al.   LEUKEMIA

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia

(2008) Sylvie D. Freeman et al.   SEMINARS IN ONCOLOGY